// App-Quantinova.ai

1023 : BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Researchers

Presenter

  • Peter Schmid

Principal Investigators

  • Seock-Ah Im

  • Anne Armstrong

  • Yeon Hee Park

  • Wei-Pang Chung

  • Zbigniew Nowecki

  • Simon Lord

  • Piotr Jan Wysocki

  • Yen-Shen Lu

  • Hannah Dry

  • Vatsala Karwe

  • Ross Stewart

  • Pia Herbolsheimer

  • Ana Tablante Nunes

  • Kyung Hae Jung

Medical Centers

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Cancer Research Institute, College of Medicine, Seoul National University Hospital, Seoul, South Korea

  • Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom

  • Samsung Medical Center, Seoul, Korea

  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

  • Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom

  • Jagiellonian University- Medical College-Cracow, Ophthalmology, Krakow, Poland

  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, AstraZeneca, Gaithersburg, MD, AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea

Locations

  • United Kingdom

  • Poland

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Durvalumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03742102

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved